IMVT
NASDAQImmunovant Inc.
Price$28.93-0.91 (-3.05%)
01:30 PM07:45 PM
News · 26 weeks45+700%
2025-10-262026-04-19
Mix2290d
- Insider17(77%)
- Earnings2(9%)
- SEC Filings2(9%)
- Analyst1(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Van Tuyl Christopher4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Gloria Melanie4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Stout Jay S4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Torti Frank4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Fromkin Andrew J.4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Hughes Douglas J.4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Pande Atul4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Bauer Jake4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Susman Robert Graham4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Gloria Melanie4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Stout Jay S4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Van Tuyl Christopher4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Venker Eric4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Girao Tiago4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERSEC Form 4 filed by Venker Eric4 - Immunovant, Inc. (0001764013) (Issuer)
- PRImmunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression. The hyperthyroid patients in the TED studies showed similar response rates of thyroid hormone normalization to those seen in the batoclimab Phase 2 study in Graves' diseaseImmunovant remains focused on rapid advancement of IMVT-1402 in multiple indications DURHAM, N.C., April 02, 2026 (GLOBE NEWSWIRE)
- INSIDERSEC Form 4 filed by Van Tuyl Christopher4 - Immunovant, Inc. (0001764013) (Issuer)
- ANALYSTBernstein initiated coverage on Immunovant Sciences with a new price targetBernstein initiated coverage of Immunovant Sciences with a rating of Mkt Perform and set a new price target of $28.00
- INSIDERChief Operating Officer Gloria Melanie sold $90,184 worth of shares (3,238 units at $27.85), decreasing direct ownership by 2% to 170,273 units (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)
- SECSEC Form 10-Q filed by Immunovant Inc.10-Q - Immunovant, Inc. (0001764013) (Filer)
- SECImmunovant Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Immunovant, Inc. (0001764013) (Filer)
- PRImmunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026IMVT-1402 development is progressing with potentially registrational studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren's disease (SjD) remaining on trackUnderwritten financing with key institutional investors and Roivant generated approximately $550 million in gross proceeds, extending Immunovant's cash runway
- PRImmunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About ImmunovantImmunovant,
- INSIDERChief Technology Officer Stout Jay S sold $51,461 worth of shares (1,977 units at $26.03), decreasing direct ownership by 0.99% to 197,634 units (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERChief Technology Officer Stout Jay S sold $31,914 worth of shares (1,203 units at $26.53), decreasing direct ownership by 0.60% to 199,611 units (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)